The Evolution and Clinical Applications of MRD Testing in Lymphoma - Pharmacy Times
Reid Merryman, MD, discussed the evolution of minimal residual disease (MRD) testing in lymphoma, focusing on the use of circulating tumor DNA (ctDNA) assays at the SOHO 2024 Annual Meeting. He highlighted the increased sensitivity of next-generation sequencing and the potential for MRD-guided therapy in clinical trials, emphasizing the need for standardized assays to integrate MRD into treatment decisions.
Reference News
Reid Merryman, MD, discussed the evolution of minimal residual disease (MRD) testing in lymphoma, focusing on the use of circulating tumor DNA (ctDNA) assays at the SOHO 2024 Annual Meeting. He highlighted the increased sensitivity of next-generation sequencing and the potential for MRD-guided therapy in clinical trials, emphasizing the need for standardized assays to integrate MRD into treatment decisions.